PA
IOVA icon

Profund Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Profund Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$850K Buy
204,214
+9,447
+5% +$35.9K 0.02% 392
2026
Q1 		$684K Sell
194,767
-65,893
-25% -$211K 0.03% 453
2025
Q4 		$712K Buy
260,660
+156,253
+150% +$361K 0.02% 445
2025
Q3 		$227K Buy
104,407
+41,559
+66% +$98.1K 0.01% 905
2025
Q2 		$108K Sell
62,848
-25,691
-29% -$63.9K ﹤0.01% 958
2025
Q1 		$295K Sell
88,539
-19,344
-18% -$99.8K 0.01% 689
2024
Q4 		$798K Sell
107,883
-20,921
-16% -$194K 0.03% 341
2024
Q3 		$1.21M Buy
128,804
+4,144
+3% +$39.3K 0.05% 282
2024
Q2 		$1,000K Buy
124,660
+31,010
+33% +$332K 0.04% 300
2024
Q1 		$1.39M Sell
93,650
-108,776
-54% -$1.27M 0.05% 263
2023
Q4 		$1.65M Sell
202,426
-48,084
-19% -$252K 0.07% 214
2023
Q3 		$1.14M Buy
250,510
+59,427
+31% +$388K 0.06% 255
2023
Q2 		$1.35M Sell
191,083
-10,954
-5% -$78.4K 0.07% 245
2023
Q1 		$1.23M Buy
+202,037
New +$1.39M 0.08% 246

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Profund Advisors's IOVA Position: Q2 2026 in Review

Profund Advisors increased its Iovance Biotherapeutics (IOVA) stake by 4.9% in Q2 2026, buying an estimated $35.9K and bringing the position to 204,214 shares worth $850K. The position accounts for 0.02% of the portfolio, ranked #392.

Profund Advisors first reported a position in IOVA in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.65M in Q4 2023. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Profund Advisors held 204,214 shares of Iovance Biotherapeutics worth $850K as of Q2 2026.
  • Profund Advisors bought 9,447 Iovance Biotherapeutics shares in Q2 2026, an estimated $35.9K.
  • Iovance Biotherapeutics made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #392 holding.
  • Profund Advisors first reported a position in Iovance Biotherapeutics in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Iovance Biotherapeutics position peaked at $1.65M in Q4 2023.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.